Combined treatments with metformin and phosphodiesterase inhibitors alleviate non-alcoholic fatty liver disease in high-fat diet-fed rats: A comparative study.
This study was designed to investigate the possible protective effects of metformin alone and in combination with different phosphodiesterase inhibitors (PDEIs). Rats were fed a high-fat diet (HFD) for sixteen weeks to induce NAFLD. Starting from week 12, rats received metformin alone or in combination with pentoxifylline, cilostazol or sildenafil. HFD administration resulted in hepatic steatosis and inflammation in rats. In addition, liver index, body composition index, activities of liver enzymes, and serum lipids deviated from normal. Further, significant elevations were recorded compared to control in terms of serum gl...
Source: Canadian Journal of Physiology and Pharmacology - February 21, 2020 Category: Drugs & Pharmacology Authors: Heeba GH, El-Deen R, Abdel-Latif RG, Khalifa MMA Tags: Can J Physiol Pharmacol Source Type: research
Effect of antiplatelet agent number, types, and pre-endoscopic management on post-polypectomy bleeding: validation of endoscopy guidelines
ConclusionsAnalysis of this large polypectomy dataset showed that the use of low-dose aspirin, thienopyridine, or cilostazol and a combination of these is associated with increased PPB risk. Although PPB risk was high with DAPT or TAPT, PPB rate in any antiplatelet monotherapy even with a continuing strategy was low at
Source: Surgical Endoscopy - February 6, 2020 Category: Surgery Source Type: research
Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study.
acute;rai Z Abstract Background: Symptomatic peripheral arterial disease (intermittent claudication) is a major cause of disability and mobility loss in older men and women and thus has a significant negative impact on the patients' quality of life. Both surgical and endovascular revascularization procedures and noninvasive medical therapies, such as supervised training and drug treatment, can improve walking capacity. Cilostazol is the only drug having a class I (level of evidence A) recommendation for the treatment of intermittent claudication (IC). The aim of this study was to evaluate the effect of three-mont...
Source: VASA. Zeitschrift fur Gefasskrankheiten. Journal for Vascular Diseases - January 27, 2020 Category: Surgery Authors: Farkas K, Kolossváry E, Járai Z Tags: Vasa Source Type: research
The use of cilostazol for secondary stroke prevention: isn't time to be evaluated in Western countries?
Authors: Di Napoli M, Singh P, Lattanzi S, Divani AD PMID: 31935129 [PubMed - as supplied by publisher] (Source: Expert Opinion on Pharmacotherapy)
Source: Expert Opinion on Pharmacotherapy - January 16, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Antithrombotic therapy for postinterventional management of peripheral arterial disease.
CONCLUSION: There is a considerable paucity of high-quality evidence on the optimal antithrombotic regimen for patients undergoing lower extremity revascularization, with no particular therapy shown to consistently improve patient outcomes. The decision to initiate intensified antithrombotic therapy should include a close examination of its risk-benefit profile. The demonstrated benefit of such treatment is restricted to the prevention of index artery reocclusion, while an increased risk of bleeding may lead to significant morbidity and mortality. PMID: 31930282 [PubMed - as supplied by publisher] (Source: American Jo...
Source: American Journal of Health-System Pharmacy : AJHP - January 13, 2020 Category: Drugs & Pharmacology Authors: Zavgorodnyaya D, Knight TB, Daley MJ, Teixeira PG Tags: Am J Health Syst Pharm Source Type: research
A rapid and efficient method for the collection of highly developmental murine immature oocytes using cilostazol, a phosphodiesterase 3A inhibitor
Publication date: Available online 27 November 2019Source: Life SciencesAuthor(s): Ahmed M. Taiyeb, Anas Alazzam, Michael E. Kjelland, Thaddeus H. Adams, Duane C. Kraemer, Saeeda A. Muhsen-Alanssari, Mundhir T. Ridha-AlbarzanchiAbstractAimsThe present study aims to define maturation, yield, health, and ease of collection of murine immature oocytes recovered using the conventional method or from mice treated with cilostazol.Main methodsThe conventional method included the superovulation of mice and the recovery of germinal vesicle (GV) or metaphase (MI) oocytes from preovulatory follicles. The cilostazol method included the...
Source: Life Sciences - December 7, 2019 Category: Biology Source Type: research
Utilization of a fattigation platform gelatin-oleic acid sodium salt conjugate as a novel solubilizing adjuvant for poorly water-soluble drugs via self-assembly and nanonization
In this study, gelatin and oleic acid sodium salt (OAS), a generally recognized as safe-listed material were chosen and conjugated to develop a natural solubilizing adjuvant using the fattigation platform technology to enhance solubility and dissolution rate of poorly water-soluble drugs according to self-assembly and nanonization principle when simply mixed with poorly water-soluble drugs. We synthesized the gelatin and OAS conjugates (GOC) at three different ratios (1:1, 1:3, 1:5; GOC 1, GOC 2, and GOC 3, respectively) via the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxysuccinimide reaction using a spray drye...
Source: International Journal of Pharmaceutics - November 29, 2019 Category: Drugs & Pharmacology Source Type: research
Progress in the Mechanism and Clinical Application of Cilostazol.
This article briefly reviews the pharmacological mechanisms and clinical application of cilostazol. PMID: 31763974 [PubMed - as supplied by publisher] (Source: Current Topics in Medicinal Chemistry)
Source: Current Topics in Medicinal Chemistry - November 22, 2019 Category: Chemistry Authors: Zheng H, Yang H, Gong D, Mai L, Qiu X, Chen L, Su X, Wei R, Zeng Z Tags: Curr Top Med Chem Source Type: research
Comparative effectiveness of different antiplatelet agents at reducing TNF-driven inflammatory responses in a mouse model.
In this study, we compared the anti-TNF activity of three antiplatelet agents, namely clopidogrel, sarpogrelate, and cilostazol, using the TNF-induced inflammatory mouse model. After the oral administration of these drugs, acute inflammation was induced via injection of lipopolysaccharide (LPS) or D-galactosamine (D-gal) and TNF. Serum TNF levels, and the mRNA and protein expression levels of TNF in mouse heart tissue, macrophage accumulation in aortic lesions, and mouse survival were analysed to compare the anti-TNF effects of the three antiplatelet agents. Of the three antiplatelet agents, cilostazol significantly reduce...
Source: Clinical and Experimental Pharmacology and Physiology - November 12, 2019 Category: Drugs & Pharmacology Authors: Lee HR, Park KY, Jeong YJ, Heo TH Tags: Clin Exp Pharmacol Physiol Source Type: research
Evaluation Of Pharmacokinetic Interaction of Cilostazol with Metoclopramide after Oral Administration in Human.
CONCLUSION: The results showed delayed Tmax of metoclopramide by cilostazol, which could lead to the conclusion that cilostazol affects the absorption of metoclopramide. Both drugs when necessary to administer together must not be administered at the same time especially when given in gastroparesis patients. PMID: 31702486 [PubMed - as supplied by publisher] (Source: Current Drug Metabolism)
Source: Current Drug Metabolism - November 4, 2019 Category: Drugs & Pharmacology Authors: Kaukab I, Hussain Shah SN, Kharaba Z, Murtaza G, Saad AA, Ahmad S Tags: Curr Drug Metab Source Type: research
Cilostazol Promotes Angiogenesis and Increases Cell Proliferation After Myocardial Ischemia –Reperfusion Injury Through a cAMP-Dependent Mechanism
ConclusionCilostazol could promote angiogenesis, increase cell viability and inhibit cell apoptosis, consequently protecting myocardial tissues against I/R-injury through activating cAMP. (Source: Cardiovascular Engineering and Technology)
Source: Cardiovascular Engineering and Technology - October 17, 2019 Category: Cardiology Source Type: research
Medical adjunctive therapy for patients with chronic limb-threatening ischemia: a systematic review.
uml; Ç Abstract INTRODUCTION: To systematically review the literature on medical adjunctive therapy for patients with chronic limb-threatening ischemia (CLTI). EVIDENCE ACQUISITION: MEDLINE, Embase, and Cochrane Database of Systematic Reviews were searched for studies published between January 1, 2009, and June 1, 2019. Articles that studied medical treatment of CLTI patients and reported clinical outcomes were eligible. Main exclusion criteria were case reports
Source: The Journal of Cardiovascular Surgery - October 9, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Ipema J, Roozendaal NC, Bax WA, de Borst GJ, de Vries JP, Ünlü Ç Tags: J Cardiovasc Surg (Torino) Source Type: research
Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study.
Authors: Senda J, Ito K, Kotake T, Kanamori M, Kishimoto H, Kadono I, Nakagawa-Senda H, Wakai K, Katsuno M, Nishida Y, Ishiguro N, Sobue G Abstract Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment. We investigate the potential of cilostazol for reducing or restoring cognitive decline during convalescent rehabilitation in patients with non-cardioembolic ischemic stroke. The study sample included 371 consecutive patients with lacunar (n = 44) and ath...
Source: Nagoya Journal of Medical Science - October 4, 2019 Category: International Medicine & Public Health Tags: Nagoya J Med Sci Source Type: research
Phosphodiesterase inhibitors say NO to Alzheimer's disease.
MH Abstract Phosphodiesterases (PDEs) consisted of 11 subtypes (PDE1 to PDE11) and over 40 isoforms that regulate levels of cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP), the second messengers in cell functions. PDE inhibitors (PDEIs) have been attractive therapeutic targets due to their involvement in diverse medical conditions, e.g. cardiovascular diseases, autoimmune diseases, Alzheimer's disease (AD), etc. Among them; AD with a complex pathology is a progressive neurodegenerative disorder which affect mostly senile people in the world and only symptomatic treatment particular...
Source: Food and Chemical Toxicology - September 16, 2019 Category: Food Science Authors: Nabavi SM, Talarek S, Listos J, Nabavi SF, Devi KP, Roberto de Oliveira M, Tewari D, Argüelles S, Mehrzadi S, Hosseinzadeh A, D'onofrio G, Orhan IE, Sureda A, Xu S, Momtaz S, Farzaei MH Tags: Food Chem Toxicol Source Type: research
Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells.
Abstract Cardiovascular disease is recognized as a leading cause of death worldwide, but the risk of death is 2-3 times higher for individuals with diabetes. NLRP3 inflammasome activation is a leading pathway of vascular damage, and new treatment methods are needed to reduce NLRP3 inflammasome expression, along with a detailed understanding of how those treatments work. In a series of assays on human vascular endothelial cells that were exposed to high concentrations of free fatty acids (FFA) to induce a diabetes-like environment, we found a significant impact of cilostazol, a vasodilator widely used to treat bloo...
Source: Atherosclerosis - September 15, 2019 Category: Cardiology Authors: Wang X, Huang H, Su C, Zhong Q, Wu G Tags: Artif Cells Nanomed Biotechnol Source Type: research
Cilostazol ameliorates high free fatty acid (FFA)-induced activation of NLRP3 inflammasome in human vascular endothelial cells
Volume 47, Issue 1, December 2019, Page 3704-3710 . (Source: Artificial Cells, Blood Substitutes, and Biotechnology)
Source: Artificial Cells, Blood Substitutes, and Biotechnology - September 13, 2019 Category: Biotechnology Authors: Xing Wang Huiling Huang Chen Su Qiaoqing Zhong Guifu Wu Source Type: research
Cilostazol Is Useful for the Treatment of Sinus Bradycardia and Associated Hemodynamic Deterioration Following Heart Transplantation.
Authors: Uchikawa T, Fujino T, Higo T, Ohtani K, Shiose A, Tsutsui H Abstract Bradycardia is a common complication at the early postoperative period after heart transplantation (HT). The heart rate (HR) usually recovers within a few weeks; however, several patients need a temporary pacemaker or chronotropic agents to stabilize their hemodynamics. Here, we report the first case of transient bradycardia associated with hemodynamic deterioration following HT, which was successfully treated with cilostazol, a phosphodiesterase-3-inhibiting agent. A 59-year-old man received HT for advanced heart failure due to ischemic ...
Source: International Heart Journal - September 6, 2019 Category: Cardiology Tags: Int Heart J Source Type: research
Cilostazol inhibits hyperglucose-induced vascular smooth muscle cell dysfunction by modulating the RAGE/ERK/NF- κB signaling pathways
Increasing evidence suggests that high glucose (HG) causes abnormalities in endothelial and vascular smooth muscle cell function (VSMC) and contributes to atherosclerosis. Receptor for advanced glycation end-p... (Source: Journal of Biomedical Science)
Source: Journal of Biomedical Science - September 6, 2019 Category: Biomedical Science Authors: Sheng-Chiang Su, Yi-Jen Hung, Chia-Luen Huang, Yi-Shing Shieh, Chu-Yen Chien, Chi-Fu Chiang, Jhih-Syuan Liu, Chieh-Hua Lu, Chang-Hsun Hsieh, Chien-Ming Lin and Chien-Hsing Lee Tags: Research Source Type: research
Enhancement of swallowing motor activity by the ACE inhibitor imidapril in an arterially perfused rat preparation.
In this study, we examined the effects of imidapril, cilostazol, and amantadine, which are often prescribed for swallowing disorders, on swallowing motor activity. We recorded the efferent activities of the cervical vagal nerve, hypoglossal nerve, and phrenic nerve using arterially perfused rats aged between 21-35 postnatal days. The vagal nerve activity was used for evaluation of swallowing motor activity. When 1.25 ml of distilled water was injected into the oral cavity, or the superior laryngeal nerve was electrically stimulated, synchronized swallowing bursts were evoked in the vagal and hypoglossal nerve, while insp...
Source: European Journal of Pharmacology - August 14, 2019 Category: Drugs & Pharmacology Authors: Moriya T, Nakayama K, Nakamura S, Mochizuki A, Ofuji T, Shirota T, Inoue T Tags: Eur J Pharmacol Source Type: research
Antiplatelet Therapy in Cerebral Small Vessel Disease
AbstractPurpose of ReviewWe critically evaluate the evidence for the use of antiplatelet therapy for stroke prevention following lacunar stroke and in patients with hemorrhage-prone cerebral small vessel disease.Recent FindingsPooled lacunar stroke subgroup analyses of all relevant randomized controlled trials to date suggest a 22% relative risk reduction in recurrent stroke by single antiplatelet therapy (RR 0.77, 95% CI 0.62 –0.97) compared with placebo, no consistent suggestion of variable efficacy amongst specific antiplatelet agents, and the absence of clear benefit with dual over single antiplatelet therapy. Cu...
Source: Current Neurology and Neuroscience Reports - July 27, 2019 Category: Neuroscience Source Type: research
Bioequivalence Study of 100-mg Cilostazol Tablets in Healthy Thai Adult Volunteers
ConclusionsBestazol 100-mg tablet was bioequivalent to Pletaal 100-mg tablet. Thus, the formulations can be used interchangeably in clinical practice. (Source: Current Therapeutic Research)
Source: Current Therapeutic Research - July 23, 2019 Category: Drugs & Pharmacology Source Type: research
Bioequivalence Study of 100 mg Cilostazol Tablets in Healthy Thai Adult Volunteers
This study was conducted at the Siriraj Clinical Research Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Each volunteer was initially treated according to either the Test-Reference (TR) or the Reference-Test (RT) sequence, after which each subject was switched to the other study sequence after a two-week washout period. Pharmacokinetic analysis was performed using log-transformed ratios (test/reference) for Cmax, AUC0-tlast, AUC0-∞, Tmax, t1/2, and λZ for both cilostazol and 3,4-dehydro-cilostazol (its active metabolite) with 90% confidence interval. Physical examination, ...
Source: Current Therapeutic Research - July 16, 2019 Category: Drugs & Pharmacology Source Type: research
Reduced deformability contributes to impaired deoxygenation-induced ATP release from red blood cells of older adult humans.
This article is protected by copyright. All rights reserved. PMID: 31310005 [PubMed - as supplied by publisher] (Source: The Journal of Physiology)
Source: The Journal of Physiology - July 16, 2019 Category: Physiology Authors: Racine ML, Dinenno FA Tags: J Physiol Source Type: research
Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial
Conclusions Cilostazol increased heart rate and platelet count, and reduced Buckberg index, whilst both drugs may individually reduce arterial stiffness adjusted for heart rate. Neither drug had clinically significant effects on haemoglobin or platelet function over 8 weeks. Further assessment of the safety and efficacy of these medications following lacunar ischaemic stroke is warranted. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - July 3, 2019 Category: Neurology Source Type: research
Role of and Recent Evidence for Antiplatelet Therapy in Prevention of Cardiovascular Disease in Diabetes
AbstractPurpose of ReviewWhen treating patients with diabetes mellitus (DM), the benefits of antiplatelet therapy in preventing cardiovascular disease must be weighed against an increased risk of bleeding. Recent trials have sought to determine both the optimal anti-platelet regimen for patients with DM, and who specifically requires medication among the DM population. This paper will review recent trials and evidence recommending the use of antiplatelet therapy in the prevention of cardiovascular disease in patients with diabetes.Recent FindingsSeven notable trials assessed the effectiveness of antiplatelet therapy in the...
Source: Current Cardiology Reports - June 28, 2019 Category: Cardiology Source Type: research
Large vessel vasculopathy in a patient with systemic lupus erythematosus: a case report
ConclusionsLarge vessel vasculopathy should be considered another potential cause of arterial stenoses and occlusion in patients with lupus when they have peripheral arterial disease despite having no atherosclerotic risk factors. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - June 22, 2019 Category: General Medicine Source Type: research
Multitarget-directed cotreatment with cilostazol and aripiprazole for augmented neuroprotection against oxidative stress-induced toxicity in HT22 mouse hippocampal cells.
This study highlights that cotreatment with low concentrations of aripiprazole and cilostazol synergistically elicits neuroprotective effects by overcoming oxidative stress-evoked neurotoxicity associated with increased neurite outgrowth, providing a rationale for the use of this combinatorial treatment in vascular dementia. PMID: 31202803 [PubMed - as supplied by publisher] (Source: European Journal of Pharmacology)
Source: European Journal of Pharmacology - June 13, 2019 Category: Drugs & Pharmacology Authors: Lee YS, Park SY, Heo HJ, Lee WS, Hong KW, Kim CD Tags: Eur J Pharmacol Source Type: research
Pharmacokinetic Modeling Analysis of Cilostazol and its Active Metabolites (OPC-13015 and OPC-13213) after Multiple Oral Doses of Cilostazol in Healthy Korean Volunteers.
Abstract Cilostazol is a selective inhibitor of PDE III, which is prescribed for patients with peripheral arterial disease, especially intermittent claudication. The purpose of the study was to investigate the PK of cilostazol and its metabolites on the IR formulation of cilostazol in healthy Korean male volunteers by population PK modeling analysis implemented using NONMEM software. A 2 × 2 crossover study comparing multiple oral doses of IR and SR formulations of cilostazol were conducted. Serial plasma concentrations of cilostazol and its active metabolites were used in this analysis and bes...
Source: Xenobiotica - June 10, 2019 Category: Research Authors: Cui A, Kim YH, Ghim JL, Jung JA, Cho SH, Choe S, Choi HY, Bae KS, Lim HS Tags: Xenobiotica Source Type: research
Multitarget-based cotreatment with cilostazol and celecoxib synergistically suppresses collagen-induced arthritis in mice by enhancing interleukin-10 expression.
In conclusion, serum IL-10 levels in these mice were markedly increased by cilostazol and celecoxib cotreatment, whereas elevated serum IL-1β levels were markedly reduced. Cotreatment with low-dose cilostazol and celecoxib may ensure the synergistic anti-arthritic potential. PMID: 31170675 [PubMed - as supplied by publisher] (Source: International Immunopharmacology)
Source: International Immunopharmacology - June 3, 2019 Category: Allergy & Immunology Authors: Park SY, Lee YS, Lee SY, Lee SW, Hong KW, Kim CD Tags: Int Immunopharmacol Source Type: research
Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis
In conclusion, these observations suggest low concentrations of cilostazol and celecoxib cotreatment may ensure a synergistic anti-arthritic potential. (Source: Inflammopharmacology)
Source: Inflammopharmacology - May 23, 2019 Category: Drugs & Pharmacology Source Type: research
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
Publication date: June 2019Source: The Lancet Neurology, Volume 18, Issue 6Author(s): Kazunori Toyoda, Shinichiro Uchiyama, Takenori Yamaguchi, J Donald Easton, Kazumi Kimura, Haruhiko Hoshino, Nobuyuki Sakai, Yasushi Okada, Kortaro Tanaka, Hideki Origasa, Hiroaki Naritomi, Kiyohiro Houkin, Keiji Yamaguchi, Masanori Isobe, Kazuo Minematsu, Shinya Goto, Tatsuya Isomura, Masayasu Matsumoto, Yasuo Terayama, Hidekazu TomimotoSummaryBackgroundAlthough dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of...
Source: The Lancet Neurology - May 22, 2019 Category: Neurology Source Type: research
Pharmacological Potential of Cilostazol for Alzheimer ’s Disease
Alzheimer's disease (AD), a slow progressive form of dementia, is clinically characterized by cognitive dysfunction and memory impairment and neuropathologically characterized by accumulation of extracellular plaques containing amyloid β-protein (Aβ) and neurofibrillary tangles containing tau in the brain, with neuronal degeneration and high-level of oxidative stress. The current treatments for AD, e.g., acetylcholinesterase inhibitors (AChEIs), have efficacies limited to symptom improvement. Although there are various approaches to the disease modifying therapies of AD, none of them can be used alone for actual ...
Source: Frontiers in Pharmacology - May 22, 2019 Category: Drugs & Pharmacology Source Type: research
Comparison of efficacy between trimetazidine and cilostazol in the treatment of arteriosclerosis obliterans in lower extremity.
This study compared the efficacy and long-term survival rate of trimetazidine and cilostazol in the treatment of lower extremity arteriosclerosis obliterans (ASO). A retrospectively analysis on the medical records of 206 patients with ASO who were admitted to The Central Hospital of Wuhan from January 2011 to May 2013 was performed, including 94 patients treated with trimetazidine (group A) and 112 patients treated with cilostazol (group B). On the basis of the same basic treatment, both groups were applied with these two drugs after two courses of treatments. Then the efficacy of clinical treatment, dorsal artery blood fl...
Source: Experimental and Therapeutic Medicine - May 17, 2019 Category: General Medicine Tags: Exp Ther Med Source Type: research
Pharmacokinetic study of two extended-release formulations of cilostazol in healthy Korean subjects: A randomized, open-label, multiple-dose, two-period crossover study
CONCLUSION: Cilostazol SR showed significantly higher Cmax,ss and AUCτ of cilostazol than cilostazol CR after 5 days of multiple dosing of extended-release formulations of cilostazol. . PMID: 31079600 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - May 14, 2019 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research
Vardenafil and cilostazol can improve vascular reactivity in rats with diabetes mellitus and rheumatoid arthritis co-morbidity
Publication date: Available online 11 May 2019Source: Life SciencesAuthor(s): Mariam Gamal Fahmy Wahba, Basim Anwar Shehata Messiha, Mahmoud El-Sayed El-Daly, Ali Ahmed Abo-SaifAbstractEndothelial dysfunction and vascular reactivity defects secondary to metabolic and immunological disorders carry risk of serious cardiovascular complications. Here, the effects of the phosphodiesterase (PDE) inhibitors vardenafil and cilostazol were examined against rheumatoid arthritis (RA)/diabetes mellitus (DM)-co-morbidity-induced endothelial dysfunction and vascular reactivity defects. After setting of RA/DM-co-morbidity model, rats wer...
Source: Life Sciences - May 12, 2019 Category: Biology Source Type: research
Development of a Multicomponent Intervention to Prevent Alzheimer's Disease
Recent advances in vascular risk management have successfully reduced the prevalence of Alzheimer’s Disease (AD) in several epidemiologic investigations. It is now widely accepted that cerebrovascular disease is both directly and indirectly involved in AD pathogenesis. Herein, we review the non-pharmacological and pharmacological therapeutic approaches for AD treatment. MIND (Mediterranean and DASH (Dietary Approaches to Stop Hypertension) Intervention for Neurodegenerative Delay) diet is an important dietary treatment for prevention of AD. Multidomain intervention including diet, exercise, cognitive training, and in...
Source: Frontiers in Neurology - May 8, 2019 Category: Neurology Source Type: research
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness
AbstractAntiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetes (T2D) patients. However, the efficacy and usefulness of antiplatelet drugs on the progression of carotid intima-media thickness (IMT), a marker for evaluating early atherosclerotic vascular disease, has not been analyzed. We conducted a prospective, randomized, open, 36-month trial comparing cilostazol vs. aspirin. A total of 415 T2D patients (age range 38 –83 years; 206 females) without macrovascular complications were randomized to either an aspirin (100 mg/day) or cilostazol (200 mg/day) treatment. Pat...
Source: Heart and Vessels - May 6, 2019 Category: Cardiology Source Type: research
Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcription factor EB (TFEB)
In this study, a rat model of I/R injury was constructed and quantitative real ‐time PCR, Western blot, and immunofluorescence (IF) assay were performed. Our results showed that cilostazol increased LC3 II/LC3 I ratio, reduced p62 abundance, and promoted the expressions of LAMP1, LAMP2, cathepsin B, and cathepsin D, indicating that cilostazol could activate autophagy and ele vated lysosome activation. Following analysis showed that cilostazol enhanced nuclear protein expression of transcription factor EB (TFEB), an important regulator of autophagy‐lysosome pathway. Furthermore, CCI‐779, an inhibitor of TFEB, could re...
Source: Biotechnology and Applied Biochemistry - May 1, 2019 Category: Biochemistry Authors: Jiangjin Li, Xiaoli Xiang, Zuo Xu Tags: Original Article Source Type: research
Critical limb ischemia in a patient with systemic lupus erythematosus: a case report
ConclusionCritical limb ischemia is a rare complication of systemic lupus erythematosus that requires immediate treatment. Due to our limited resources, we improvised a strategy to achieve the best possible outcome in our patient by using a combination of invasive treatment and medication. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - April 25, 2019 Category: General Medicine Source Type: research
Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case-Crossover Study
A crossover study was conducted of patients admitted for congestive heart failure (CHF) retrieved from the Taiwan National Health Insurance Database between 2009 and 2011. (Source: Journal of Vascular Surgery)
Source: Journal of Vascular Surgery - April 19, 2019 Category: Surgery Authors: C.K. Wu, J.W. Lin, L.C. Wu, C.H. Chang Tags: Cilostazol (Pletal) should not be used to treat claudication in diabetics Source Type: research
Cilostazol protects against myocardial ischemia and reperfusion injury by activating transcrption factor EB (TFEB)
This article is protected by copyright. All rights reserved (Source: Biotechnology and Applied Biochemistry)
Source: Biotechnology and Applied Biochemistry - April 17, 2019 Category: Biochemistry Authors: Jiangjin Li, Xiaoli Xiang, Zuo Xu Tags: Original Article Source Type: research
A Comparison of the Anti-Inflammatory Effects of Four Combined Statin and Antiplatelet Therapies on Tumor Necrosis Factor-Mediated Acute Inflammation < b > < i > in vivo < /i > < /b >
Conclusions: The combination therapy comprising cilostazol and statins, particularly pravastatin, exerted the best anti-TNF effect compared with clopidogrel and statin therapy; thus, a suitable combination therapy, such as CILOP, can be a potential remedy to cure TNF-related diseases.Pharmacology 2019;104:21 –27 (Source: Pharmacology)
Source: Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research
Efficacy of cilostazol for sick sinus syndrome to avoid permanent pacemaker implantation: A retrospective case-control study.
Abstract BACKGROUND: Currently, bradycardia treatment is limited to permanent pacemaker (PM) implantation. No consensus exists as to its optimal medication regimen. However, as cilostazol accelerates heart rate (HR) in bradycardia, we investigated its efficacy for sick sinus syndrome (SSS) to avoid permanent PM implantation. METHODS: This was a retrospective, case-control study. We included 192 consecutive patients diagnosed with SSS (after applying some exclusion criteria), of whom 54 received cilostazol (cilostazol group) and 138 did not receive cilostazol (control group). The primary endpoint was the PM im...
Source: Journal of Cardiology - April 11, 2019 Category: Cardiology Authors: Sonoura T, Kodera S, Shakya S, Kanda J Tags: J Cardiol Source Type: research
Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition.
Authors: Vandenberghe P, Delvaux M, Hagué P, Erneux C, Vanderwinden JM Abstract Despite the introduction of tyrosine kinase inhibitors, gastrointestinal stromal tumors (GIST) resistance remains a major clinical challenge. We previously identified phosphodiesterase 3A (PDE3A) as a potential therapeutic target expressed in most GIST. The PDE3 inhibitor cilostazol reduced cell viability and synergized with the tyrosine kinase inhibitor imatinib (Gleevec™) in the imatinib-sensitive GIST882 cell line. Here, we found that cilostazol potentiated imatinib also in the imatinib-resistant GIST48 cell line. Cilost...
Source: Oncotarget - April 9, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Food effect on meal administration time of pharmacokinetic profile of cilostazol, a BCS class II drug.
Abstract 1. Cilostazol (CLZ) is categorized as a BCS class II drug. CLZ suspensions of jet-milled particles were orally administered to beagle dogs in fasted and fed states, for which food was given 0.5 h before the experiment. 2. The mean highest concentration of CLZ (Cmax) and the area under the serum concentration-time curve (AUCt) fed/fasted ratios were 2.90 and 2.85, respectively, indicating a large and variable food effect. Additionally, CLZ was administered to the same dogs at 2 and 4 h after food or 0.5 h before food. The serum concentrations of CLZ were similar when dosed 0.5 and 2&th...
Source: Xenobiotica - April 2, 2019 Category: Research Authors: Miyake M, Oka Y, Mukai T Tags: Xenobiotica Source Type: research
The Effect of Cilostazol on Hippocampal Memory and Oxidative Stress Biomarkers in Rat Model of Diabetes Mellitus.
In conclusion, cilostazol showed no improvement in the learning and memory functions which could be due to the lack of significant cognitive impairment induced by streptozotocin administration. However, cilostazol had shown antioxidant activity through normalization of hippocampal oxidative stress biomarkers. PMID: 30914251 [PubMed - as supplied by publisher] (Source: Brain Research)
Source: Brain Research - March 23, 2019 Category: Neurology Authors: Rababa'h AM, Mardini AN, Alzoubi KH, Ababneh MA, Athamneh RY Tags: Brain Res Source Type: research